- Fellowship - UT MD Anderson Cancer Center (2007-2010), Hematology Oncology
- Medical School - UT Southwestern Medical School (1999-2003)
- Residency - UT Southwestern Medical Center (2003-2006), Internal Medicine
Suzanne Cole, M.D.
Medical Director, Community Oncology, Simmons Comprehensive Cancer Center
- Internal Medicine - Hematology/Oncology
- General Hematology/Oncology
Biography
Suzanne Cole, M.D., FACP, FASCO, is an Associate Professor in the Division of Hematology and Oncology, Department of Internal Medicine at UT Southwestern Medical Center. She serves as the Medical Director and Research Leader of Community Oncology at the Harold C. Simmons Comprehensive Cancer Center. Dr. Cole’s leadership focuses on expanding access to clinical trials to cancer patients in Community Oncology, Rural, and Underrepresented Minority (CORUM) populations, aiming to ensure diverse patient participation in cancer research.
Originally from North Dakota, Dr. Cole earned both a B.S. in biology and a B.A. in modern dance, summa cum laude, from the University of Texas at Dallas. She pursued a Master of Arts in humanities from California State University Northridge, graduating with distinction. Dr. Cole earned her medical degree from UT Southwestern, where she also completed her residency in internal medicine. She then underwent advanced fellowship training in hematology and medical oncology at the University of Texas MD Anderson Cancer Center in Houston.
Before joining UT Southwestern in 2018, Dr. Cole spent eight years providing cancer care in community and rural settings in West Virginia and Oklahoma, which deepened her commitment to improving access to excellent cancer care for underserved populations. Dr. Cole practices the entire spectrum of hematology and oncology, with a clinical focus in genitourinary (GU) malignancies, and she has built a robust cancer clinical trial program within UT Southwestern’s community clinics located in Richardson-Plano, Redbird, and Fort Worth.
Dr. Cole is board certified in hematology and medical oncology and is a Fellow of both the American College of Physicians (FACP) and the American Society of Clinical Oncology (FASCO). She has been recognized for her extraordinary volunteer service and commitment to ASCO, where she has held numerous roles, including on the Cancer Communications Committee, Diversity and Inclusivity Task Force, Women’s Networking Center, and Practice Guidelines Implementation Network. She is also a graduate of ASCO's Leadership Development Program. Dr. Cole has been deeply embedded in conducting research beyond academic medical centers, working closely within the National Cancer Institute/National Clinical Trials Network groups ECOG-ACRIN and SWOG to develop clinical trials in kidney cancer, bladder cancer, prostate cancer, lung cancer, and Real World Data.
In addition to her professional achievements, Dr. Cole is an advocate for integrating humanity into medicine, writing narrative medicine stories that highlight the experiences of her patients and their families. She has presented nationally and published widely in peer-reviewed journals, including The New England Journal of Medicine, The Lancet, and Blood, on cancer and blood disorders. She is also the founder of the Hematology & Oncology Women Physician Group and has served on the board of the Oklahoma Society of Clinical Oncology.
Meet Dr. Cole
Medical Oncologist and Hematologist in Dallas
Dr. Suzanne Cole and her team provide compassionate care for patients with cancer and blood-related disorders in a welcoming, community clinic.
Throughout her career, Dr. Cole has cared for cancer and hematology patients. With cancer in particular, she says, it’s vital for patients to fully trust their physicians.
“With cancer treatment, you’re putting your life into the hands of that care team,” she says. “There should be a human connection between the patient and the oncologist. A foundation of trust is essential. Each patient needs guidance that comes with honesty, empathy, and compassion.”
Dr. Cole proudly brings that level of care to each and every patient at the Richardson/Plano and Redbird clinics. Her goal is to deliver UT Southwestern’s exceptional standard of care to the northern suburbs, giving cancer and hematology patients a convenient location to receive their chemotherapy or immunotherapy infusions and other medical treatments.
“Truly a Calling”
Dr. Cole recognizes that oncology and hematology can be challenging fields that aren’t necessarily a good fit for every physician. But ever since her medical training, she’s known that this was the type of work she was meant to do.
“This specialty is truly a calling,” she says. “And there is nothing I would rather do with my time than dedicate my life to finding a way to help people stay alive in the face of this life-threatening disease. I find such great honor in doing this important work. It really is a matter of life and death for my patients – and a matter of finding their way to a good life while going through cancer treatment. I see myself as a soldier in the trenches, walking with my patients, guiding them, fighting for them in their daily battles.”
Dr. Cole and her team work closely with patients to ensure the best treatment for each individual’s specific circumstances. She says for some it means finding a path for the patient to survive cancer; for others, the goal is to help patients endure treatment or live longer and maintain as much quality of life as possible in the face of terminal cancer.
Leading-edge Treatments
Although for most patients a cancer diagnosis is a life-changing event, Dr. Cole and her team work to make it manageable – not only through compassionate, patient-centered care, but also by providing the best of what UT Southwestern has to offer: some of the leading physician scientists in medicine, the most leading-edge technology, and the latest cancer research.
Dr. Cole is encouraged to see emerging cancer treatments, such as immunotherapy, that are revolutionizing cancer care. As a strong advocate of oncology research, she is always looking for ways to advance the field. One way she does this is by encouraging her patients to participate in clinical trials, which provide access to new and emerging treatments that could prove to be life-saving.
“Cancer research is crucial to moving a deadly disease toward a survivable one,” she says. “Improving access to and enrollment of patients into cancer clinical trials is vital to finding a path to a cure. I was shocked to learn that in the United States less than 5 percent of cancer patients enroll in clinical trials. Clinical trials often provide access to the latest and most promising breakthrough medications that ultimately go on to improve survival from this deadly disease.”
Dr. Cole says one of the reasons that so few patients participate in clinical trials is that they are often conducted in large medical universities, while most cancer patients receive their cancer care close to home in smaller hospital or clinic settings without access to research. However, she’s looking to change that for her patients in Dallas.
“One of the great joys and passions in my career has been building programs to expand access to allow patients to participate in clinical trials in the local clinic facilities where they receive care,” she says. “If you have cancer, you should not be denied access to a potentially life-saving clinical trial just because you live two hours away.”
For patients in Dallas, this is just one of the ways Dr. Cole is working to make her clinic a convenient location for high-quality care while also acting as a partner and advocate for each patient who walks through her door.
Education & Training
Professional Associations & Affiliations
- American College of Physicians (2006-2025), Fellow as of 2015
- American Society of Clinical Oncology (2008-2025), Fellow as of 2023
- American Society of Hematology (2010-2025)
- SWOG Cancer Research Group (2018-2022), Co-Chair Community Engagement Corp
- ECOG-ACRIN Cancer Research Group (2019-2025), Member of Genitourinary Committee, Real World Data Committee
Honors & Awards
- Outstanding Clinical Medicine Resident Teaching Award 2004-2005, UT Southwestern Medical Center
- Letter of Commendation for Patient Care Services 2015, Charleston Area Medical Center
- Top Doctor, Medical Oncology 2017-2018, Oklahoma Magazine
- Congressional Commendation for Medical Relief during Hurricane Harvey 2017, Congressman Ralph Abraham, Louisiana 5th Congressional District, US House of Representatives
- J.W. Norwood Distinguished Alumni Award 2017, Burleson High School
- NCI Outstanding Clinical Trial Accrual Silver Physician Award 2018, National Cancer Institute Community Oncology Research Program
- Best Doctor, Medical Oncology 2020-2024, D Magazine
- Distinguished Alumni Award 2022, University of Texas at Dallas
- Outstanding Undergraduate Medical Education Faculty Teaching Award in Internal Medicine 2024, UT Southwestern Medical Center
- America's Best Prostate Cancer Oncologists 2024, Newsweek
Books & Publications
-
Books
-
ASCO Education Book Editorial Board
(2020-2024) -
ASCO Education Book. 2019 Jan; Vol 39: page 96-104. in Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions.
Cole S, Zibelman M, Bertino E, Yucebay F, Reynolds K. (2019), doi: 10.1200/EDBK_100018. Epub 2019 May 17. PMID: 31099682, American Society of Clinical Oncology
-
ASCO Education Book Editorial Board
-
Publications
-
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE, The New England journal of medicine 2024 Sep -
Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer.
Holland L, Bhanvadia R, Ibeziako N, Taylor J, Gerlt D, Chaplin I, Bagrodia A, Desai N, Gaston K, Lotan Y, Margulis V, Zhang T, Cole S, Woldu S, Urologic oncology 2024 Jul -
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, Drake CG, Signoretti S, Akgul M, Baniak N, Li-Ning E, Palmer MB, Emamekhoo H, Adra N, Kaimakliotis H, Ged Y, Pierorazio PM, Abel EJ, Bilen MA, Ogan K, Moon HH, Ramaswamy KA, Singer EA, Mayer TM, Lohrey J, Margulis V, Gills J, Delacroix SE, Waples MJ, James AC, Wang P, Choueiri T, Michaelson MD, Kapoor A, Heng DY, Shuch B, Leibovich BC, Lara PN, Manola J, Maskens D, Battle D, Uzzo R, Bratslavsky G, Haas NB, Carducci MA, The Lancet. Oncology 2024 Jun -
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
Gerald T, Margulis V, Meng X, Bagrodia A, Cole S, Qin Q, Call SG, Mauer E, Lotan Y, Woldu SL, Urologic oncology 2023 Mar 41 3 148.e17-148.e24 -
Who Should Be Responsible for Relief of Financial Toxicity?
Symington BE, Abdel Karim NF, Kenney LB, Cole SM, Crawley MA, Kaur GNMN, Sullivan JE, JCO oncology practice 2022 Mar OP2100885 -
The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis.
Goksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF, Leukemia & lymphoma 2022 Feb 1-9 -
Women Oncologists' Perceptions and Factors Associated With Decisions to Pursue Academic vs Nonacademic Careers in Oncology.
Merfeld EC, Blitzer GC, Kuczmarska-Haas A, Pitt SC, Chino F, Le T, Allen-Rhoades WA, Cole S, Marshall AL, Carnes M, Jagsi R, Duma N, JAMA network open 2021 Dec 4 12 e2141344 -
Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.
Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R, Advances in radiation oncology 2021 Sep-Oct 6 5 100692 -
Effect of Doxorubicin on Myocardial Bicarbonate Production from Pyruvate Dehydrogenase in Women with Breast Cancer.
Park JM, Reed GD, Liticker J, Putnam WC, Chandra A, Yaros K, Afzal A, MacNamara JP, Raza J, Hall RG, Baxter J, Derner K, Pena S, Kallem RR, Subramanyan I, Edpuganti V, Harrison C, Muthukumar A, Lewis C, Reddy S, Unni N, Klemow D, Syed S, Li HC, Cole SM, Froehlich T, Ayers CR, de Lemos JA, Malloy CR, Haley B, Zaha VG, Circulation research 2020 Oct -
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C, Butler P, Bagrodia A, Cole S, Subramaniam RM, AJR. American journal of roentgenology 2020 08 215 2 267-276 -
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME, Future oncology (London, England) 2019 May 15 15 1683-1695 -
Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions.
Cole S, Zibelman M, Bertino E, Yucebay F, Reynolds K, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2019 Jan 39 96-104 -
Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians.
Graff SL, Close J, Cole S, Matt-Amaral L, Beg R, Markham MJ, Journal of oncology practice 2018 12 14 12 e758-e769 -
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Aug 16 8 1122-9 -
Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature.
Cole S, Kantarjian H, Ault P, Cortés JE, Clinical lymphoma & myeloma 2009 Aug 9 4 324-7 -
An integrated (2)H and (13)C NMR study of gluconeogenesis and TCA cycle flux in humans.
Jones JG, Solomon MA, Cole SM, Sherry AD, Malloy CR American journal of physiology. Endocrinology and metabolism 2001 Oct 281 4 E848-56
-
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Research
- Grantor: FDA Title of Project: “Real-World Data to Generate Real-World Evidence in Regulatory Decision Making” Role: Co-Principal Investigator: Suzanne Cole, MD, Peter O’Dwyer, MD, Al Benson, MD, Victoria Wang, PhD
- Grantor: National Cancer Institute, National Institute of Health Title of Project: Phase II trial of SAbR for Oligometastatic Renal Cell Carcinoma Co-Principal Investigator: Suzanne Cole, MD, Raquibal Hannan, MD
- Grantor: Merck Title of Project: Phase II trial of preoperative use of axitinib and pembrolizumab for locally advanced renal cell carcinoma with IVC tumor thrombus prior to surgical consolidation Co-Principal Investigators: Suzanne Cole, MD, Xiaosong Meng, MD, Vitaly Margulis, MD
Clinical Focus
- General Hematology/Oncology
Q&A by Dr. Cole
Results: 2 Locations
Simmons Cancer Center
at UT Southwestern Medical Center at RedBird 3450 W. Camp Wisdom RoadDallas, Texas 75237 (214) 645-4673 Directions to Simmons Cancer Center Parking Info for Simmons Cancer Center
Simmons Cancer Center
at UT Southwestern Medical Center at Richardson/Plano 3030 Waterview Parkway, 2nd FloorRichardson, Texas 75080 972-669-7077 Directions to Simmons Cancer Center